Vimarsana
Biggest News Aggregation in the World

Page 20 - Amy Wolf News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Amy Wolf. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Amy Wolf Today - Breaking & Trending Today

The Eyes Offer a Window into Alzheimer's Disease - Vimarsana News

The Eyes Offer a Window into Alzheimer's Disease

While it has been said that the eyes are a window to the soul, a new study shows they could be a means for understanding diseases of the brain. According to new research by scientists at the UCSF Weill Institute for Neurosciences, retinal scans can detect key changes in blood vessels that may provide an early sign of Alzheimer’s disease, while offering important insights into how one of the most common Alzheimer's risk genes contributes to the disease.  “The most prevalent genetic risk for Alzheimer’s disease is a variant of the APOE gene, known as APOE4,” said lead aut...

Source: ucsf.edu
Novartis Pharma AG: Novartis Phase III Beovu data show potential for fluid resolution in more diabetic macular edema patients with fewer injections versus aflibercept - Vimarsana News

Novartis Pharma AG: Novartis Phase III Beovu data show potential for fluid resolution in more diabetic macular edema patients with fewer injections versus aflibercept

Novartis Pharma AG: Novartis Phase III Beovu data show potential for fluid resolution in more diabetic macular edema patients with fewer injections versus aflibercept 1 More patients treated with Beovu 6 mg experienced fluid (IRF/SRF) resolution at week 32 and week 52 versus aflibercept; fluid is a key marker of disease activity in DME 1 1 Phase III KESTREL and KITE trials are the first pivotal trials to assess an anti-VEGF on six-week dosing intervals in the loading phase, suggesting Beovu may offer fewer injections from the start of treatment 1 Novartis is committed to bringing Beovu 6 mg t...

Investegate |NOVARTIS AG CHF0.50(REGD) Announcements | NOVARTIS AG CHF0.50(REGD): Novartis Phase III Beovu® data show potential for fluid resolution in more diabetic macular edema patients with fewer injections versus aflibercept - Vimarsana News

Investegate |NOVARTIS AG CHF0.50(REGD) Announcements | NOVARTIS AG CHF0.50(REGD): Novartis Phase III Beovu® data show potential for fluid resolution in more diabetic macular edema patients with fewer injections versus aflibercept

NOVARTIS AG CHF0.50(REGD) Novartis Phase III Beovu® data show potential for fluid resolution in more diabetic macular edema patients with fewer injections versus aflibercept Novartis Phase III Beovu® data show potential for fluid resolution in more diabetic macular edema patients with fewer injections versus aflibercept In KESTREL and KITE, Beovu (brolucizumab) 6 mg met the primary endpoints of non-inferiority in change in best corrected visual acuity from baseline versus aflibercept 2 mg at year one in diabetic macular edema (DME) patients 1 More patients treated with Beovu 6 mg experience...

OAN to pay MSNBC, Rachel Maddow $250K in defamation lawsuit - Vimarsana News

OAN to pay MSNBC, Rachel Maddow $250K in defamation lawsuit

“We literally learned today that that outlet the president is promoting shares staff with the Kremlin,” Maddow said in a July 22, 2019, episode. “In this case, the most obsequiously pro-Trump right wing news outlet in America really literally is paid Russian propaganda. The on air U.S. politics reporter is paid by the Russian government to produce propaganda for that government.” MUNCIE, IN – DECEMBER 02: Rachel Maddow discusses the headlines of the day in Emens Auditorium at Ball State University, David Letterman’s alma mater, on December 2, 2011 in Muncie, Indiana. (Photo by Ro...

MSNBC, Rachel Maddow awarded $250,000 in legal fees after OAN lawsuit - Vimarsana News

MSNBC, Rachel Maddow awarded $250,000 in legal fees after OAN lawsuit

One America News Network was ordered to pay MSNBC and host Rachel Maddow nearly $250,000 in legal fees after a failed defamation lawsuit.